The hepatitis C virus life cycle as a target for new antiviral therapies.
about
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patientsAntiviral drugs for viruses other than human immunodeficiency virusAnalysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis CUpdate on hepatitis C: Direct-acting antiviralsOral antiviral therapies for chronic hepatitis C infectionComputational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural CompoundsHepatitis C virus host cell interactions uncoveredRelative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon SystemSustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte filmsHepatitis C Virus Infection Induces Apoptosis through a Bax-Triggered, Mitochondrion-Mediated, Caspase 3-Dependent PathwayFluorescence Resonance Energy Transfer-Based Assay for Characterization of Hepatitis C Virus NS3-4A Protease Activity in Live CellsA Cooperative Interaction between Nontranslated RNA Sequences and NS5A Protein Promotes In Vivo Fitness of a Chimeric Hepatitis C/GB Virus BPerformance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA QuantificationToll-Like Receptor 3 Mediates Establishment of an Antiviral State against Hepatitis C Virus in Hepatoma CellsHepatitis C Virus Proteins Induce Lipogenesis and Defective Triglyceride Secretion in Transgenic MiceHepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical PracticeMouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell LineAmphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral EntryFurther Insights into the Roles of GTP and the C Terminus of the Hepatitis C Virus Polymerase in the Initiation of RNA SynthesisInhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral interventionGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankVirtual Screening and Molecular Dynamics Simulations from a Bank of Molecules of the Amazon Region Against Functional NS3-4A Protease-Helicase Enzyme of Hepatitis C Virus.Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingHuman liver transplantation as a model to study hepatitis C virus pathogenesisSeroconversion to hepatitis C virus alternate reading frame protein during acute infection.Development of hepatitis C virus vaccines: challenges and progress.Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma.Antiviral treatment for hepatitis C virus infection after liver transplantation.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Hepatocellular carcinoma xenograft supports HCV replication: a mouse model for evaluating antivirals.Rapid emergence of protease inhibitor resistance in hepatitis C virus.Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.A perspective on modelling hepatitis C virus infection.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein.Poly(C)-binding protein 2 interacts with sequences required for viral replication in the hepatitis C virus (HCV) 5' untranslated region and directs HCV RNA replication through circularizing the viral genome.
P2860
Q24624237-87115394-211C-44BD-879E-6485040D96A6Q24635330-034AF3AD-27C2-474B-BCF9-EE72BE5CCA1BQ26773283-C8F45F54-9CF6-4373-BF03-0B6C24606C7CQ26775809-030FC5E0-E754-428D-A11F-255618F6415EQ26830426-0ECC02D6-4096-4AFB-B5F1-44B57D8869B0Q27307600-D5C6771D-BBE6-495F-B925-880598B682B6Q27480989-57723A78-262C-4D67-9369-029BB53C0314Q27485441-A964A8C8-7CB3-4EAD-97C3-871941E75670Q27487098-E9105AFA-0ADD-4AA7-9511-56343EA52D3EQ27487135-F604035E-792E-4E17-9E02-88FD7F5145C3Q27487770-BC35C0B7-27B0-41D3-B59C-FF4F137DBEC9Q27487865-709B5A2F-8DEB-4FB8-9E56-9977D905C923Q27488563-8F96A7B7-9195-4A30-AD1C-BCECC6EAA12EQ27489687-FB6C2EC5-B5AC-4142-B753-C61EED0E6CE5Q27490446-594B0716-EAF5-4355-A4AC-12E7DFA51919Q27490447-CCE8F635-628A-4ABB-9212-D3AED347A2FDQ27490526-7318B6BB-1B75-4DC4-AE88-796E66FB8F9BQ27490785-5685E43B-DD8F-4E77-8C92-DD2D772EAEB0Q27664120-C53020D5-19D8-4885-B6FA-62448E3B0C28Q27684795-C08451FE-8C10-4E13-A3A5-6035917AA972Q28553430-C46D4646-57EE-4518-BBD8-B9DA4DA54F69Q33457358-58D4DC80-D42B-4700-81AF-8F20124DC492Q33672648-B876E916-C26C-4933-BB80-A954B6A8698BQ33802605-CFB7B233-0C2C-4D6B-B5A1-E7AF50FC1ED4Q33876447-A9696D4B-2B40-48DB-8E87-63C8581E8F8EQ33899320-588FBBD2-ECF7-4271-8AAC-CBD2076B0BA1Q34197528-9A97A64B-5C7F-4AC7-BD82-CC948EBD201AQ34208658-B347E7C1-DEE8-4F6D-8156-AE658B1FF4F0Q34254941-406EE658-43B7-4420-8FA4-610AF272C028Q34297798-63F402C4-A49F-4D70-80C0-C7CE45CE655EQ34340293-471CA655-6E6F-4250-8C92-7D6C62D26E5EQ34409020-00DD7186-14D7-4919-8980-9F600B9DEE90Q34497429-78969BC2-352C-4529-86A6-57D7301E7022Q34551913-914B3057-3016-45C9-B980-AE3DC0BF47FDQ34587192-444B2775-6FE5-4890-A794-661364BC69D1Q34626479-BD17C53B-80C3-4FC4-BA3A-E325FE8AF538Q34759489-CAAEA498-F83F-479B-B92D-9C120489DE3EQ34957256-9B2FE6B3-DB7D-4EBD-881D-182D3559CAD4Q35108971-90256C58-1073-48CB-A9C8-7FAE1876DC8EQ35140492-A86E7283-0955-48D8-83B5-B68DC6D75FE6
P2860
The hepatitis C virus life cycle as a target for new antiviral therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The hepatitis C virus life cycle as a target for new antiviral therapies.
@ast
The hepatitis C virus life cycle as a target for new antiviral therapies.
@en
type
label
The hepatitis C virus life cycle as a target for new antiviral therapies.
@ast
The hepatitis C virus life cycle as a target for new antiviral therapies.
@en
prefLabel
The hepatitis C virus life cycle as a target for new antiviral therapies.
@ast
The hepatitis C virus life cycle as a target for new antiviral therapies.
@en
P2093
P1433
P1476
The hepatitis C virus life cycle as a target for new antiviral therapies.
@en
P2093
Jean-Michel Pawlotsky
John G McHutchison
Stéphane Chevaliez
P304
P356
10.1053/J.GASTRO.2007.03.116
P407
P577
2007-05-01T00:00:00Z